1. Home
  2. LSTA vs LITB Comparison

LSTA vs LITB Comparison

Compare LSTA & LITB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LSTA
  • LITB
  • Stock Information
  • Founded
  • LSTA 1980
  • LITB 2007
  • Country
  • LSTA United States
  • LITB Singapore
  • Employees
  • LSTA N/A
  • LITB N/A
  • Industry
  • LSTA Misc Health and Biotechnology Services
  • LITB Catalog/Specialty Distribution
  • Sector
  • LSTA Health Care
  • LITB Consumer Discretionary
  • Exchange
  • LSTA Nasdaq
  • LITB Nasdaq
  • Market Cap
  • LSTA 20.0M
  • LITB N/A
  • IPO Year
  • LSTA N/A
  • LITB N/A
  • Fundamental
  • Price
  • LSTA $2.21
  • LITB $1.02
  • Analyst Decision
  • LSTA Strong Buy
  • LITB
  • Analyst Count
  • LSTA 1
  • LITB 0
  • Target Price
  • LSTA $15.00
  • LITB N/A
  • AVG Volume (30 Days)
  • LSTA 17.1K
  • LITB 21.3K
  • Earning Date
  • LSTA 02-27-2025
  • LITB 03-24-2025
  • Dividend Yield
  • LSTA N/A
  • LITB N/A
  • EPS Growth
  • LSTA N/A
  • LITB N/A
  • EPS
  • LSTA N/A
  • LITB N/A
  • Revenue
  • LSTA $1,000,000.00
  • LITB $333,093,000.00
  • Revenue This Year
  • LSTA N/A
  • LITB N/A
  • Revenue Next Year
  • LSTA N/A
  • LITB N/A
  • P/E Ratio
  • LSTA N/A
  • LITB N/A
  • Revenue Growth
  • LSTA N/A
  • LITB N/A
  • 52 Week Low
  • LSTA $2.05
  • LITB $0.91
  • 52 Week High
  • LSTA $4.20
  • LITB $6.00
  • Technical
  • Relative Strength Index (RSI)
  • LSTA 38.28
  • LITB 37.97
  • Support Level
  • LSTA $2.05
  • LITB $0.92
  • Resistance Level
  • LSTA $2.46
  • LITB $1.05
  • Average True Range (ATR)
  • LSTA 0.20
  • LITB 0.05
  • MACD
  • LSTA 0.01
  • LITB 0.01
  • Stochastic Oscillator
  • LSTA 32.81
  • LITB 38.46

About LSTA Lisata Therapeutics Inc.

Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively.

Share on Social Networks: